Janus Kinase Inhibitors in Dermatology: A Systematic Review

April 2017 in “ Journal of the American Academy of Dermatology ”

Rony Shreberk‐Hassidim, Yuval Ramot, Abraham Zlotogorski

Janus kinase inhibitors JAK inhibitors alopecia areata psoriasis vitiligo dermatitis cutaneous T cell lymphoma lupus erythematosus

TLDR JAK inhibitors help with skin conditions but need more research on dosing and safety.

This systematic review from 2017 evaluated the use of Janus kinase (JAK) inhibitors in dermatology by analyzing 134 articles, including 78 original articles and 18 clinical trials. JAK inhibitors showed beneficial results for psoriasis, comparable to etanercept, and favorable outcomes for alopecia areata. Preliminary positive results were also noted for vitiligo, dermatitis, graft versus host disease, cutaneous T cell lymphoma, and lupus erythematosus. The most common adverse events were infections, particularly nasopharyngitis and upper respiratory tract infections. However, the review highlighted gaps in knowledge regarding the correct dosing and safety profile of JAK inhibitors, indicating a need for further trials.

View this study on jaad.org →

Discuss this study in the Community →

Cited in this study

14 / 14 results

research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents

139 citations , January 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , January 2017 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

$Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman$

research Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman

24 citations , January 2017 in “Acta dermato-venereologica”

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers

70 citations , July 2016 in “Experimental Dermatology”

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations , December 2014 in “Journal of Investigative Dermatology”

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

2 / 2 results

research Serum Zinc Concentration in Patients With Alopecia Areata

October 2023 in “Acta dermato-venereologica (Print)”

People with severe hair loss have lower zinc levels in their blood.

research Inhibiting Janus Kinases to Treat Alopecia Areata

52 citations , September 2014 in “Nature medicine”

JAK inhibitors might help treat alopecia areata.

Janus Kinase Inhibitors in Dermatology: A Systematic Review

Cited in this study

research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

research Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers

research Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients

research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis

research Topical Ruxolitinib for the Treatment of Alopecia Universalis

research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis

research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata

research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

Related

research Serum Zinc Concentration in Patients With Alopecia Areata

research Inhibiting Janus Kinases to Treat Alopecia Areata